ELXM.F Stock Overview
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nova Eye Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.19 |
| 52 Week Low | AU$0.10 |
| Beta | 0.79 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -68.75% |
| 5 Year Change | -83.33% |
| Change since IPO | -86.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELXM.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.3% |
| 1Y | n/a | -0.6% | 24.2% |
Return vs Industry: Insufficient data to determine how ELXM.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how ELXM.F performed against the US Market.
Price Volatility
| ELXM.F volatility | |
|---|---|
| ELXM.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ELXM.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ELXM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | n/a | Tom Spurling | www.nova-eye.com |
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally.
Nova Eye Medical Limited Fundamentals Summary
| ELXM.F fundamental statistics | |
|---|---|
| Market cap | US$30.74m |
| Earnings (TTM) | -US$7.42m |
| Revenue (TTM) | US$10.25m |
3.0x
P/S Ratio-4.1x
P/E RatioIs ELXM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELXM.F income statement (TTM) | |
|---|---|
| Revenue | AU$15.23m |
| Cost of Revenue | AU$3.06m |
| Gross Profit | AU$12.17m |
| Other Expenses | AU$23.19m |
| Earnings | -AU$11.02m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 79.94% |
| Net Profit Margin | -72.40% |
| Debt/Equity Ratio | 7.3% |
How did ELXM.F perform over the long term?
See historical performance and comparison